Literature DB >> 9151959

Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).

L C Petersen1.   

Abstract

The two zymogens, plasminogen and pro-urokinase plasminogen activator (pro-uPA), constitute a system of reciprocal activation, since plasmin, generated by uPA-catalysed plasminogen activation, can activate pro-uPA to uPA. Two such zymogens, when mixed, will undergo autocatalytic, reciprocal activation resulting in generation of proteolytic activity. As an example of reciprocal zymogen activation, the plasminogen/pro-uPA system was analysed in terms of a kinetic model which describes the progression in activated enzymes. This model gave a detailed description of the progress curves in plasmin and uPA. It accounted for the effects of varying the concentration of the zymogens, and also for the effects of plasmin substrates and inhibitors in the reaction mixture. The model assumes non-significant zymogen activity. It did not, however, exclude that a very low initial proteolytic activity, accounting for maximally 0.01% of that obtained when pro-uPA is fully activated, could be attributed to a genuine pro-uPA activity. Binding of the uPA receptor (uPAR) to pro-uPA/uPA might affect separate steps of the reciprocal activation reaction, or it might induce a significant pro-uPA activity. To distinguish between these possibilities the effect of a recombinant soluble (residues 1-277) form of uPAR, uPAR-(1-277)-peptide, on reciprocal pro-uPA/plasminogen activation was studied. uPAR-(1-277)-peptide attenuated reciprocal zymogen activation, and the results suggested that this was due to a decreased accessibility of the pro-uPA/uPAR-(1-277)-peptide complex to activation by plasmin. The uPAR-(1-277)-peptide in the presence of poly(D-lysine) caused a 20-fold enhancement of reciprocal zymogen activation. Kinetic analysis of separate activation steps revealed that this was due to a threefold stimulation of plasminogen activation by uPA/uPAR-(1-277)-peptide combined with a sixfold stimulation of plasmin's activation of pro-uPA/uPAR-(1-277)-peptide. The results suggested that poly(D-lysine) provided a template for a catalytically favourable interaction between plasminogen/plasmin and the uPAR-(1-277)-peptide complex with pro-uPA/uPA. There was no indication of a significant uPAR-(1-277)-peptide-induced enhancement of pro-uPA activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151959     DOI: 10.1111/j.1432-1033.1997.00316.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  10 in total

Review 1.  Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke.

Authors:  Rais Reskiawan A Kadir; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2019-09-24       Impact factor: 5.046

2.  Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.

Authors:  Feng-Pai Chou; Ya-Wen Chen; Xianfeng F Zhao; Zijun Y Xu-Monette; Ken H Young; Ronald B Gartenhaus; Jehng-Kang Wang; Hiroaki Kataoka; Annie H Zuo; Robert J Barndt; Michael Johnson; Chen-Yong Lin
Journal:  Am J Pathol       Date:  2013-10       Impact factor: 4.307

3.  Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.

Authors:  R Pannell; S Li; V Gurewich
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

4.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

5.  Expression of full-length human pro-urokinase in mammary glands of transgenic mice.

Authors:  Yaroslav Gursky; Robert Bibilashvili; Mikchail Minashkin; Alex Krasnov; Alex Deikin; Tatyana Ermolkevich; Andrey Popov; Lilia Verbovaya; Nicolai Rutkevich; Alexsander Shevelev; Sofia Georgieva; Sergey V Razin; Igor Goldman; Elena Sadchikova
Journal:  Transgenic Res       Date:  2009-04-25       Impact factor: 2.788

Review 6.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

7.  Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.

Authors:  Ralph Pannell; Shelley Li; Victor Gurewich
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 8.  Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement.

Authors:  Victor Gurewich
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

9.  A candidate activation pathway for coagulation factor VII.

Authors:  Tina M Misenheimer; Kraig T Kumfer; Barbara E Bates; Emily R Nettesheim; Bradford S Schwartz
Journal:  Biochem J       Date:  2019-10-15       Impact factor: 3.857

10.  The use of thromboelastography to assess post-operative changes in coagulation and predict graft function in renal transplantation.

Authors:  Carson B Walker; Hunter B Moore; Trevor L Nydam; Alexander C Schulick; Hillary Yaffe; James J Pomposelli; Michael Wachs; Thomas Bak; Kendra Conzen; Megan Adams; Thomas Pshak; Rashikh Choudhury; Michael P Chapman; Elizabeth A Pomfret; Peter Kennealey
Journal:  Am J Surg       Date:  2020-08-27       Impact factor: 2.565

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.